Table 2. Confirmed best overall tumor response per Response Evaluation Criteria in Solid Tumors V.1.1.
| Dose escalation cohorts | Dose expansion cohorts | Study overall | ||||
|---|---|---|---|---|---|---|
| Overall | MCC | CSCC | Melanoma | SC | ||
| Evaluable patients, n | 19 | 11 | 4 | 9 | 8 | 51 |
| CR, n (%) | 2 (10.5) | 1 (9.1) | 0 | 0 | 0 | 3 (5.9) |
| PR, n (%) | 2 (10.5) | 0 | 0 | 0 | 1 (12.5) | 3 (5.9) |
| SD, n (%) | 0 | 2 (18.2) | 1 (25.0) | 3 (33.3) | 2 (25.0) | 8 (15.7) |
| PD, n (%) | 15 (78.9) | 8 (72.7) | 3 (75.0) | 6 (66.7) | 5 (62.5) | 37 (72.5) |
| ORR, n (%) | 4 (21.1) | 1 (9.1) | 0 | 0 | 1 (12.5) | 6 (11.8) |
| DCR, n (%) | 4 (21.1) | 3 (27.3) | 1 (25.0) | 3 (33.3) | 3 (37.5) | 14 (27.5) |
CR, complete response; CSCC, cutaneous squamous cell carcinoma; DCR, disease control rate; MCC, Merkel cell carcinoma; n, number of patients; ORR, overall response rate; PD, progressive disease; PR, partial response; SC, subcutaneous; SD, stable disease.